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Neural stem cells (NSCs) lie at the heart of central nervous system development and repair, and deficiency or
dysregulation of NSCs or their progeny can have significant consequences at any stage of life. Immune
signaling is emerging as one of the influential variables that define resident NSC behavior. Perturbations in
local immune signaling accompany virtually every injury or disease state, and signaling cascades that
mediate immune activation, resolution, or chronic persistence influence resident stem and progenitor cells.
Some aspects of immune signaling are beneficial, promoting intrinsic plasticity and cell replacement, while
others appear to inhibit the very type of regenerative response that might restore or replace neural networks
lost in injury or disease. Here we review known and speculative roles that immune signaling plays in the post-
natal and adult brain, focusing on how environments encountered in disease or injury may influence the
activity and fate of endogenous or transplanted NSCs.Introduction
Neural stem cells (NSCs) play many roles during prenatal devel-
opment and throughout adult life. Although it is an oversimplifi-
cation to classify NSCs as being identical at all stages of life,
many of the regulatory mechanisms that control stem cell
behavior are conserved in development and in the adult. While
the specific identity of NSCs in vivo is still debated, there are cells
present within the central nervous system (CNS) at all stages of
life that self renew and have the capacity to generate all three
major cell types of the CNS: neurons, astrocytes, and oligoden-
drocytes. The earliest NSCs arise as a single layer of columnar
neuroepithelium that forms the neural tube and gives rise to
neuron or glia-restricted progenitor cells. Through sequential
proliferation and differentiation, neuroectodermal stem cells ulti-
mately generate the entire CNS during prenatal and early post-
natal development (Merkle and Alvarez-Buylla, 2006).
Stem and progenitor cells continue to produce neurons and
glia well into childhood and maintain low-level cell replace-
ment/addition throughout life (Ming and Song, 2005). Although
glial progenitor cells are abundant and mediate continued
production of glia throughout the brain, the natural production
of new neurons is restricted to two locations in the adult: the sub-
ventricular zone (SVZ), which generates neuroblasts that migrate
to the olfactory bulb where they participate in networks that
mediate olfaction; and the subgranular zone (SGZ) of the hippo-
campal dentate gyrus, which generates granular cell layer
neurons involved in networks that modulate mood as well as
short-term learning andmemory (Franklin and Ffrench-Constant,
2008; Ming and Song, 2005).
It is thought that stem cells residing in other areas of the brain
have similar potential to generate neurons and that injury can
evoke an abortive production of new neurons outside of the
two neurogenic areas, a fleeting phenomenon that provides
a sliver of hope for future NSC-based therapies (Carmichael,
2008). However, the local signaling within these areas clearly
restricts both the abundance and type of cell produced, andthe practical effect is that the mature CNS does not undergo
substantial regeneration. The dogma of ‘‘no new neurons’’ is
well deserved in virtually all regions of the adult brain. Accumu-
lating evidence suggests that failure to produce neurons is not
due to the absence of cells that could mediate neurogenesis,
since removal of NSCs from many areas of the brain allows
them to generate neurons in vitro (Palmer et al., 1999), but rather
due to local signaling that tightly constrains neurogenesis to
a diminutive level in vivo (Dayer et al., 2005; Tamura et al.,
2007). Ultimately, there is a broad continuum of homeostatic
signals that act on self-renewing multipotent stem cells,
committed progenitor cells, and the terminally differentiated
cells of the brain to control function, daily maintenance, and
minor repair (Ming and Song, 2005). Understanding these signals
may provide methods for modifying or amplifying neural progen-
itor cell (NPC) response for repair.
Restoration of damaged neural networks in the adult remains
one of the strongest forces driving research in NSC biology, and
the study of the native process of neurogenesis within the hippo-
campus or olfactory system continues to provide new insights
into how this might be achieved. The complex signaling environ-
ments that regulate the production of neurons and glia are adap-
tive and can respond to changes in local demand. For example,
within the hippocampus, the production of new neurons is stim-
ulated by local neuronal network activity, physical activity (such
as running), environmental enrichment, and even simply the act
of learning (Duan et al., 2008; Emsley et al., 2005). In the olfactory
bulb, exposure to novel smells or other experiences that provide
olfactory enrichment also promotes the production and retention
of new neurons (Magavi et al., 2005; So et al., 2008). The impli-
cation is that areas that can produce neurons are more efficient
at producing and retaining new neurons when natural demand
on the local network is high.
Conversely, chronic stress and depression, as well as local or
systemic inflammation, are potent inhibitors of neurogenesis
(Butovsky et al., 2006; Cameron and Gould, 1994; Ekdahl et al.,Neuron 64, October 15, 2009 ª2009 Elsevier Inc. 79
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Figure 1. Immune Response in the CNS
Immune signaling in the CNS follows a well-character-
ized and stereotypical progression. 1. The innate
immune response is stimulated as a consequence of
infection, injury, or cell death, which releases mole-
cules recognized by Toll-like receptors. The initial
immune recognition and signaling cascade is medi-
ated primarily by astrocytes (A) and microglia (MG),
tissue resident cells that recognize and respond to
molecular patterns released by pathogens or
damaged cells. Astrocytes and microglia are also
well known for their intimate contact with the vascula-
ture astrocytic end feet, which form a tight vascular
barrier that modulates immune cell and cytokine traf-
ficking from the periphery. Toll-like receptor activation
initiates production of proinflammatory cytokines and
chemokines. Key among these are tumor necrosis
factor-a (TNF-a), interferon- g (INF- g), interleukin-6
(IL-6), and IL-1b. 2. The adaptive immune response is
triggered by these cytokines and involves the activa-
tion and recruitment of peripheral leucocytes to sites
of infection or injury. Cytokines act locally to activate
cells of the vasculature and act within the circulation
to activate circulating lymphocytes, which then bind
to activated endothelium and extravasate into the
site of immune response. Relative to other tissues of
the body, peripheral lymphocyte recruitment is attenu-
ated by the astrocytic blood-brain barrier (BBB), but
injuries that damage the BBB or aggressive acute
proinflammatory signaling can degrade BBB function
and permit a full-scale adaptive response. Lympho-
cytes, along with tissue-resident immune cells, then
mediate the elimination of pathogens through antigen
presentation, recognition, and amplification of effector T and B cells. 3. Immune regulation and resolution of the innate and adaptive responses follows clearance
of the initiating molecular patterns and Fas-ligand (FasL)-mediated apoptosis of effector lymphocytes. The HPA axis, lymphocytes, macroglia, microglia, and
neurons all further contribute to the production of anti-inflammatory hormones and cytokines such as glucocorticoids (via the HPA axis), TGF-b, IL-10, and IL-4.2003; Monje et al., 2003; Tanapat et al., 1998). Disease and injury
states also invoke immune and stress responses, and under-
standingboth thenatural positiveandnegativesignalingnetworks
that regulate NSCs in these unique neurogenic areas is
relevant for designing future strategies to enhance regeneration.
While the global effects of manipulating an animal’s health or
experience on adult neurogenesis are incontrovertible, the
specific molecules or cells that mediate each effect are still hotly
debated. The intimate coregulation ofmood, stress response, the
hypothalamic-pituitary-adrenal (HPA) axis, and immune cytokine
signaling makes it even more difficult to uncouple the specific
effects of one physiology from another. For example, chronic
stress is a well-known inhibitor of NSC-mediated hippocampal
neurogenesis. Early work implicated the HPA axis and elevated
glucocorticoids as the primary inhibitory mechanism (Cameron
and Gould, 1994; Tanapat et al., 1998), while more recent work
shows that the stress effects are equally dependent on inter-
leukin-1b (IL-1b) signaling, one of the cardinal proinflammatory
cytokines (Koo and Duman, 2008). In this case, the primary insult
is not an immune challenge or tissue damage but rather a life
experience or other environmental stressor that operates through
an immune signaling intermediate. The complexity of feedback/
feedforward interactions (both systemic and local to the CNS)
highlight the hazards that lie ahead in charting the role of immune
signaling in adult neural stem and progenitor cell biology.
Immune Signaling in the CNS
The immune system is best known for its protective role in the
response to pathogens and tissue injury. An immune response80 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.follows a stereotypical sequence of events (Figure 1). Infection,
injury, or cell death initially triggers a local innate immune
signaling cascade, mediated primarily by tissue resident cells
that respond to pathogen-associated molecular patterns or
proteins released by damaged cells. These molecular patterns
bind and activate Toll-like receptors (TLRs) expressed by both
immune cells and glia within the brain. Receptor activation initi-
ates a proinflammatory cascade involving the transcriptional up-
regulation and subsequent release of proinflammatory cytokines
and chemokines in numerous cell types. In the brain, microglia
as well as microglia and neurons express TLRs and associated
cytoplasmic signaling elements (Bsibsi et al., 2002). Microglia
are the largest source of proinflammatory cytokines following
immune challenge. Cytokines then aid in the second phase of
the immune response, the activation and recruitment of periph-
eral immune cells to sites of infection or injury. Dozens of
signaling molecules are released in this first response, but the
primary mediators of the initial proinflammatory cascade include
tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and IL-1b.
Cytokines act locally as well as within the circulation to activate
vasculature and circulating lymphocytes. Circulating lympho-
cytes then bind to activated endothelium and extravasate into
the site of immune response. Along with tissue-resident immune
cells, they then mediate the elimination of pathogens through
antigen recognition and T-cell-mediated cytolysis and B-cell-
mediated antibody production.
The amplitude and duration of the immune response is largely
self limiting, because the molecular patterns that trigger and
sustain the innate response are cleared and the effector T cells
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during inflammation also elevates glucocorticoid synthesis,
which further attenuates proinflammatory signaling, and ulti-
mately, the acute proinflammatory cytokine signaling cascade
is superseded by an immunoregulatory profile of cytokines,
many of which, such as transforming growth factor-b (TGF-b),
IL-4, and IL-10, have anti-inflammatory properties (Elenkov and
Chrousos, 2002). Direct brain-immune interactions also regulate
the amplitude of the systemic immune response, mediated in
large part by parasympathetic cholinergic signaling that acts to
regulate the systemic elaboration of TNF-a (Wang et al., 2003).
In the end, immune activation in the brain invokes both local
and systemic responses through tightly coupled neuro-immune
interactions at many levels.
Although the brain was once thought to be an immune privi-
leged tissue, it is now recognized that classical immune
responses do occur within the CNS, albeit with slightly different
characteristics than in the periphery (Bailey et al., 2006). As for
other tissues that utilize immune adaptations, such as the eye
or the uterus during pregnancy, the brain utilizes a series of
molecular mechanisms that attenuate the entry of leukocytes
into the brain parenchyma and tightly regulate T-cell-mediated
adaptive immune recognition. This is accomplished in part by
constitutive expression of Fas ligand (FasL) by astrocytes and
neurons, which triggers the FasL-mediated apoptosis of acti-
vated T cells (Niederkorn, 2006). However, when the immune
stimulus or injury is sufficiently large, resident glial cells (both
astrocytes andmicroglia) are capable of producing a full comple-
ment of cytokines and chemokines and subsequently mediating
the recruitment and activation of cells of the peripheral immune
system (Bailey et al., 2006).
Glial activation, and particularly microglial activation, is a hall-
mark of inflammation in the CNS. Activated astroglia and micro-
glia produce a host of immunemediators, andmany studies over
the last few years have shown that this immune signaling is able
to perturb adult NSC activity and fate. NSCs themselves express
receptors and ligands related to the innate and adaptive immune
responses, including TLRs, a variety of cytokine and chemokine
receptors, major histocompatibility complex I (MHC I), and nu-
merous cell adhesion molecules utilized for extravasation by
lymphocytes (Covacu et al., 2009; Imitola et al., 2004; Johansson
et al., 2008; Pluchino et al., 2003; Rolls et al., 2007; Tran et al.,
2007). The range of molecules expressed supports the surpris-
ingly broad influence of signaling molecules previously thought
relevant only to cells of the immune system.
Tissue injury, degenerative disease, or infection in the CNS is
invariably accompanied by immune activation (Bailey et al.,
2006), but the impact of activated microglia or astroglia and the
effectors they release proves to be complex, because immune
signaling has both proinflammatory and proregenerative compo-
nents that undergo temporal and contextual changes. The litera-
ture is rife with conflicting reports about the specific influence of
a given molecular ligand or receptor, perhaps due in part to the
dynamic nature of this response and the varied roles that a given
cell or cytokine can play within the changing inflammatory envi-
ronment. For example, conditioned media from normal microglia
has been shown to increase neurogenesis in cultures of NSCs,
while others show that conditioned media inhibits neurogenesis(Aarumet al., 2003; Nakanishi et al., 2007). Other reports discrim-
inate between resting, activated, and immunomodulatory (or
anti-inflammatory) microglial states, each having minimal, nega-
tive, or positive effects, respectively (Butovsky et al., 2006;Monje
et al., 2003). In many cases, conflicting data can later be recon-
ciledby taking into account thebroader role that eachcell or cyto-
kine might play in the ongoing symphony of immune signaling. In
a sense, immunesignaling is never absent but insteadmaintained
in a constant balance betweenquiet but active surveillance, stim-
ulus response, andmodulation of the response to restore watch-
ful vigilance (Figure 1).
The Impact of Inflammatory Signaling on Adult
Neurogenesis
One point on which agreement seems to have been reached is
that acute activation of local or systemic innate proinflammatory
cascades has a profound negative effect on postnatal and adult
neurogenesis (Figure 2). Proinflammatory signaling can be
experimentally modeled in many ways, but one of the most
commonmethods is through the injection of pathogenmolecular
patterns that mimic viral or bacterial infections. Commonly,
researchers use viral mimics such as polyinosinic:polycytidylic
acid (poly I:C) or bacterial cell wall components such as lipopoly-
saccharide (LPS), each potent activators of the innate immune
system via TLRs. LPS injection is more widely used to model
neuroinflammation and produces an acute innate response
through activation of TLR4. LPS activation leads to a variety of
responses in immune cells, including the production of cytokines
and chemokines and the activation of antigen-presenting cell
functions to promote recruitment of the adaptive immune system
(Uematsu and Akira, 2006). LPS infused chronically into the brain
causes widespread microglial and astroglial activation and
strongly suppresses neurogenesis in the adult rodent hippo-
campus (Ekdahl et al., 2003). Remarkably, even a single injection
of LPS into the periphery of rodents is sufficient to cause a chain
of immune signaling in the periphery that ultimately causes
microglial activation in the brain and suppresses neurogenesis
in the hippocampus (Monje et al., 2003). Hippocampal neuro-
genesis can be partially restored by broad spectrum nonste-
roidal anti-inflammatory drugs (NSAIDs) under these conditions
(Bastos et al., 2008; Monje et al., 2003), suggesting that simple
immunomodulatory approaches can be beneficial. In addition,
one of the target pathways, prostaglandin synthesis, appears
to be key in this process because the absence of prostaglandin
receptors E1 and E2 protects neurogenesis from the inflamma-
tory signaling cascade evoked by LPS (Keene et al., 2009).
Although system-wide modulation of immune signaling does
influence the amplitude of effect on neurogenesis, there is still
considerable uncertainty about the specific NSC intrinsic versus
extrinsic signaling that mediates these effects.
NSCs reportedly express TLR4 in the adult SVZ, and some
have reported that TLR activation might influence NSC prolifera-
tive activity (Covacu et al., 2009; Rolls et al., 2007). It is possible,
although not yet shown, that hippocampal NSCs also express
TLR4 in vivo, which could give them the ability to directly
respond to LPS. However, animals appear to have normal levels
of BrdU labeling and production of immature neurons in the
hippocampus immediately after LPS challenge, indicating thatNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 81
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Figure 2. Impact of Proinflammatory
Signaling on Neurogenesis in the Adult
(A and B) Neurogenesis naturally occurs within the
dentate gyrus (DG) of the adult mouse hippo-
campal formation. Neural stem cells (NSCs) divide
to produce progeny that differentiate into an
abundant population of doublecortin-expressing
newborn neurons (white). These immature neurons
decorate a thin neurogenic lamina underlying the
granular cell layer (GCL).
(C) As for other regions in the brain, Iba-1-stained
microglia (white) in the DG send highly ramified
processes throughout the tissues, leaving no cell
untouched. This intimate association with all cells
of the brain allows microglia to constantly and
efficiently monitor for infection or cell death and
respond by initiating an innate immune response.
(D) Under normal conditions, the neurogenic niche
of the hippocampus strongly favors the production
of new neurons (N). This involves first generating
a transient amplifying neuroblast (NB) pool, which
subsequently differentiate and mature to become
integrated within the preexisting neural networks.
Within this region, oligodendrocytes and astro-
cytes are also produced, though to a much lesser
extent. Neurogenesis is supported in this region
as well as within the SVZ of the olfactory system
by local cues, some of which are provided by cells
of the vasculature. In other areas of the brain, oligo-
dendrocytes are the primary product of cycling
progenitor cells.
(E) Upon activation of the innate proinflammatory
response, NSCbehavior is strongly altered to favor
oligodendrocyte production. Of the proinflamma-
tory cytokines released in this initial cascade, IL-6 andTNF-aarewell known for their inhibitory effects onneurogenesis. Although TGF-balso plays a role in immune
modulation and resolution, it has pleiotropic effects in immune signaling and is also known to impair neurogenesis when chronically overproduced (Buckwalter
et al., 2006). In combination, these cytokines impair NB proliferation and reduce survival, maturation, and integration of newly generated postmitotic neurons.
Scale bars: 100 mm in (A); 25 mm in (B) and (C).LPS does not directly inhibit the proliferation or initial neuronal
fate of NSCs (Bastos et al., 2008; Ekdahl et al., 2003). Yet if the
animals are sacrificed at later times after BrdU administration,
the total number of surviving BrdU-labeled newborn neurons is
decreased (Bastos et al., 2008; Ekdahl et al., 2003; Monje
et al., 2003), suggesting that the inflammatory cascade is inhib-
iting neuron maturation and survival rather than influencing the
NSC proliferative activity directly. Though again, results seem
to differ between groups, with some reporting TLR-mediated
effects on undifferentiated stem cells with others finding no
evidence of a direct effect in vitro (Bastos et al., 2008; Monje
et al., 2003). One confounding variable is that LPS preparations
are not always equivalent and can show varied specificity for
TLR4 versus other TLR family members, and the genetic
modeling to selectively ablate TLR4 only within NSCs versus
differentiating neuroblasts has not yet been done.
The consequences of proinflammatory signaling on NSCs go
beyond simple changes in the abundance of new neurons.
Recent evidence also suggests that those few neurons that are
produced during an inflammatory episode are functionally
altered (Jakubs et al., 2008). The neurons generated during the
period of inflammation are morphologically normal, with normal
cell body location, polarity, and branching, yet they display an
accentuated inhibitory or excitatory responses in immature
versus mature neurons, respectively (Jakubs et al., 2008). This
implies that both the quantity of new neurons and the synaptic
quality of newborn neurons are affected by immune signaling.82 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.The effects of LPS-induced inflammation on the brain are not
limited to micro and macroglia, but microglia do become
strongly activated and are likely to be themost significant source
of cytokines that inhibit neurogenesis (Ekdahl et al., 2003; Monje
et al., 2003). Microglia are ubiquitous and highly ramified
throughout the CNS, and this complex arborization ensures
that all cells of the brain are capable of intimate communication
with the primary immunemonitoring cells of the CNS (Figure 2C).
Activation of microglia with LPS causes the production of factors
in vitro, including TNF- a and IL-6, that inhibit the generation of
neurons from NSCs (Monje et al., 2003). However, modification
of microglial status by other cytokines, such as IL-4 or low
dose interferon-g (IFN-g), changes their phenotype to strongly
promote neurogenesis (Butovsky et al., 2006). The positive
effects are at least partly dependent on microglia production of
insulin-like growth factor-1 (IGF-1), a potent proneurogenic
growth factor. Though controversial, this raises the possibility
that some types of controlled inflammation may be exploited in
CNS regeneration or in combating neurological diseases that
have pronounced chronic proinflammatory components (Rolls
et al., 2009; Schwartz, 2000).
Inflammation and Impact on NSCs and Neurogenesis
in Neurological Disease
NSCs have the ability to mediate limited repair in the CNS;
however, this process is largely limited to the production of oligo-
dendrocytes or astrocytes and rarely achieves a full restoration
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group has reported the regeneration of complex long-tract
projection neurons following a highly selective and nontraumatic
elimination of cortical projection neurons (Magavi et al., 2000).
Here, caged compounds were used to retrogradely label
neurons and photo-activated apoptosis caused precise dropout
of cortical projection neurons while provoking very little collateral
damage or inflammation. Although an interesting proof-of-prin-
ciple experiment, injury conditions this ‘‘clean’’ rarely exist in
real life. By the time a degenerative disease becomes clinically
detected, inflammation is rampant and endogenous neuronal
repair, if present, is influenced by the ongoing inflammatory
processes. In a disease setting, it is likely that proinflammatory
signaling plays a central role in inhibiting neuronal replacement
in the CNS. Immunomodulation may be an important adjunct
therapy in many contexts and several disease or injury models
are beginning to shed light on how immune signaling influences
the endogenous or transplanted NSC.
Insights from Neurodevelopment
Although immune signaling is highly relevant in adult disease or
injury, the potential effects of inflammation on networks
produced during fetal development are equally relevant and
provide a plausible mechanism by which immune modulation
duringpregnancymightproduce far-reaching functional changes
in the adult (see accompanying reviews in this issue ofNeuron by
Boulanger, 2009, and Deverman and Patterson, 2009). Recent
observations show that molecules classically involved in the
immune response are also naturally involved in CNS develop-
ment (Huh et al., 2000; Ma et al., 1998; Stevens et al., 2007;
Zou et al., 1998), and it seems likely that lessons learned in devel-
opmental models may have relevance in the adult.
Many groups have reported an epidemiologic linkage between
maternal infection during pregnancy with neurodevelopmental
disease in the offspring, including developmental delay, cerebral
palsy, schizophrenia, and autism (Ellman and Susser, 2009, this
issue ofNeuron). The link between schizophrenia and autism and
maternal infection appears to occur early in gestation (late first or
second trimester) (Beversdorf et al., 2005; Brown et al., 2000;
Meyer et al., 2007), a time at which NSCs in the brain are rapidly
cycling and generating neurons. Multiple reports confirm that an
inflammatory challenge to a pregnant rodent can lead to behav-
ioral abnormalities in the offspring (Meyer et al., 2006; Shi et al.,
2003; Zuckerman et al., 2003). In a mouse model of maternal
immune activation by poly I:C or maternal viral infection at
embryonic days 9.5–12.5, there are lower numbers of Purkinje
cells in the postnatal brain and some appear to be ectopically
placed (Shi et al., 2009). This is consistent with altered NSC
proliferation or neuronal progenitor migration through cytokine
signaling in the fetal brain, which can occur following maternal
inflammation (Cai et al., 2000). Indeed, maternal blockade of
the inflammatory cytokine IL-6 restores normal behavior in
mice exposed to prenatal inflammation (Smith et al., 2007). It
appears that similar mechanisms are conserved between
NSCs in development and in the adult because overexpression
of IL-6 by astrocytes in the adult also impairs neurogenesis
within the hippocampus (Vallieres et al., 2002), and much can
be gleaned from the ongoing neurodevelopmental studies for
potential applications in adult NSC biology.Neuroinflammation and Impaired Postnatal
Neurogenesis following Treatment for Pediatric Brain
Cancers
Cranial radiation therapy is crucial to the successful treatment
of many primary brain tumors, cancers metastatic to the brain,
CNS involvement of leukemia/lymphoma, and head and neck
cancers. Unfortunately, irradiation of the brain causes a debili-
tating cognitive decline in the years following treatment, espe-
cially in young children (Monje and Palmer, 2003). It has been
hypothesized that this cognitive decline is in part due to the abla-
tion of NPCs and the dependent processes of postnatal gliogen-
esis and neurogenesis. Rodent models showed that the effects
of irradiation were surprisingly selective for neurogenesis (Monje
et al., 2002). Isolation of NPCs from the irradiated brain showed
that NPCs were present and capable of generating neurons, but
for some reason were not being utilized within the adult hippo-
campus. It was subsequently determined that irradiation injury
induced a chronic inflammatory state that did not resolve and
that treatment of irradiated rodents with NSAIDs was able to
partially restore hippocampal neurogenesis (Monje et al., 2002,
2003). These results, along with similar data on inflammatory
inhibition of neurogenesis in an epilepsy model (Ekdahl et al.,
2003), were the first to uncover the ties between neurogenesis
and inflammatory signaling. Subsequent studies have confirmed
that the normally abortive regenerative response evoked by
injury such as stroke can also be potentiated by simple NSAID-
mediated attenuation of the proinflammatory response (Hoehn
et al., 2005).
A Balance of Inductive and Inhibitory Stimuli in Epilepsy
In animals, the induction of status epilepticus causes a dramatic
increase in neurogenesis in the hippocampus for 2 weeks
following the initiation of seizures (Parent et al., 1997), in part
due to the large increase in neuronal activity that promotes the
generation of new neurons. Network activity within the hippo-
campus amplifies neurogenesis through several mechanisms.
NSCs can sense local elevations in excitatory neural transmitters
that are released when networks are active (Deisseroth et al.,
2004), and the resulting signaling through NMDA receptors and
L-type calcium channels promotes transcriptional activation of
proneural genes within the NSC. Elevated network activity can
also cause transcriptional alterations in mature neurons, leading
to persistent changes in the transcription of neuron-produced
growth factors such as VEGF or BDNF, each also known to
promote neurogenesis through their direct actions on NSC and
NPCs (Ma et al., 2009; Schmidt and Duman, 2007; Segi-Nishida
et al., 2008).
In contrast, at longer time points after the seizure, neurogene-
sis is severely depressed (Bonde et al., 2006; Borges et al., 2003;
Hattiangady et al., 2004) and is accompanied by evidence of
gliosis and neurodegeneration (Blumcke et al., 2001). Persistent
microglial activation accompanies the seizure activity, and treat-
ment of mice that have experienced seizures with the anti-
inflammatory drug minocycline further increases the abundance
of new neurons surviving following seizure (Ekdahl et al., 2003).
Minocycline is used primarily as an antibiotic with good blood-
brain barrier permeability, but it also used extensively for its
effective nonsteroidal anti-inflammatory properties (Kim and
Suh, 2009). Emerging evidence suggests it may also have directNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 83
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elusive (Kim and Suh, 2009). In this experimental seizure model,
minocycline treatment decreased the number of activated
microglia in the brain while increasing the number of newborn
neurons, and this effect was seen even in the context of little
overt tissue damage (Ekdahl et al., 2003). In contrast, a
commonly used cyclooxygenase-2 (COX-2) selective inhibitor
actually has the opposite effect and inhibits neurogenesis
induced by seizures, which may be due to direct effects on
COX-2 activity in NSCs (Jung et al., 2006). In epilepsy, while later
stages would appear to benefit from increased neurogenesis,
the robust native increase in neurogenesis immediately after
seizure is likely pathogenic (Parent et al., 1997). Here, the timing
of an intervention may be critical. Use of anti-inflammatory strat-
egies to increase neurogenesis at the onset of seizure activity
may be counterproductive while immunomodulatory drugs to
target the later period of degeneration and impaired neurogene-
sis may be beneficial. It is likely that inflammation is one of
several factors that mediate the decline in neurogenesis in
chronic epilepsy, because alterations in proneurogenic growth
factors or the depletion of NSCs could also play a role (Hattian-
gady and Shetty, 2008).
Neurogenesis, Stress, and Clinical Depression
The hippocampus and its interactions with the limbic system are
thought to be critical to the pathogenesis of depression (Sahay
and Hen, 2007). Patients with depression generally show
decreases in hippocampal volume and deficits in hippo-
campus-dependent learning and memory similar to those noted
in animals following chronic stress. In animals, stress is accom-
panied by decreased hippocampal neurogenesis and there has
been speculation that the absence of neurogenesis may itself
lead to depression. However, current evidence suggests that
loss of neurogenesis is not causative (Sahay and Hen, 2007)
but may in play an unsuspected role in mediating the relative effi-
cacy of antidepressants that inhibit serotonin reuptake (Malberg
et al., 2000; Santarelli et al., 2003). In the absence of neurogen-
esis this class of antidepressants has little effect in animals.
Depression is often the consequence of severe chronic stress
and, as mentioned above, proinflammatory cytokines such as
IL-1b also appear to be involved in the reduction of neurogenesis
in animal models of depression (Goshen et al., 2008; Koo and
Duman, 2008). Given the dynamic interactions between HPA
axis, glucocorticoid modulation of immune signaling, the gluco-
corticoid and cytokine effects on neurogenesis and consequent
efficacy of selective serotonin reuptake inhibitors (SSRIs) in treat-
ing depression, it seems likely that novel therapies for depression
may ultimately include targeted manipulation of immune
signaling or other approaches that promote neurogenesis.
Multiple Sclerosis, Oligodendrogenesis, and Evidence
for Reciprocal Signaling betweenNSCand ImmuneCells
Multiple sclerosis (MS) is an autoimmune demyelinating disease
of the CNS characterized by an early loss of white matter
followed later by degeneration of the demyelinated neurons.
A large amount of work has focused on how to replace oligoden-
drocytes (the myelinating cells of the CNS), which are lost during
disease. There are two types of progenitor cells that have the
capacity to generate oligodendrocytes: the NSC and the more
lineage-restricted oligodendrocyte progenitor cell (OPC). Natu-84 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.rally occurring OPCs are capable of remyelinating axons under
some circumstances, especially in toxin-induced models of
demyelination in rodents (Franklin and Ffrench-Constant,
2008). However, these are acute models that lack the chronic
inflammation in the CNS of MS patients. In patients, some
remyelination may occur natively, but the process ultimately
fails to restore normal nerve conduction (Franklin and Ffrench-
Constant, 2008).
The focus on oligodendrocyte generation by NSCs or OPCs in
MS offers different challenges from diseases that require neuron
generation. Not only do NSCs in the SVZ naturally generate
OPCs and oligodendrocytes, but OPCs migrate and are present
throughout the neuraxis (Franklin and Ffrench-Constant, 2008).
Furthermore, inflammation, thought to be detrimental to neuro-
genesis, may actually promote the generation and functional
maturation of oligodendrocytes. In three distinct models of
demyelination, artificially increasing the level of inflammation in
the area promotes remyelination from endogenous or exoge-
nous OPCs, possibly due to the induction of growth factors
that support oligodendrocyte development (Foote and Blake-
more, 2005; Glezer et al., 2006; Setzu et al., 2006). However,
these authors examined genetic and toxin-induced models of
demyelination with acute inflammatory stimuli. In MS patients,
where inflammation is chronic and specifically targets the oligo-
dendrocyte, the potential detrimental effects of inflammation
may prevail (also see accompanying review by Bhat and Stein-
man, 2009, this issue of Neuron, for more information on
neural-immune crosstalk in MS).
OPCs are present in MS plaques, but they ultimately fail to re-
myelinate denuded axons (Kuhlmann et al., 2008; Wolswijk,
1998). Recent in vivo evidence suggests this failure is due to
a block in the differentiation of these cells rather than their
survival or recruitment (Kuhlmann et al., 2008). It therefore
appears that the environment is a key factor in remyelination
failure in MS, and the presence of chronic inflammation is a likely
factor. Several cytokines, including IFN-g, TNF-a, and IL-1b,
have been reported to block OPC differentiation, as well as
proliferation and survival, in vitro (Agresti et al., 1996; Andrews
et al., 1998; Vela et al., 2002).
Overall, this work suggests that a simple NSC or OPC trans-
plant strategy for the treatment of this disease is unlikely to be
successful due to the hostile environment to remyelination.
However, several groups have shown that transplant of NSCs,
derived from human embryonic stem cells (hESCs) or adult
mouse SVZ, into mouse models of MS are effective in amelio-
rating disease symptoms (Aharonowiz et al., 2008; Pluchino
et al., 2003, 2005). Surprisingly, in two of these three studies,
the authors were unable to detect a significant amount of trans-
planted cells differentiating into myelinating oligodendrocytes,
and failed to detect any increased remyelination despite the
functional improvement (Aharonowiz et al., 2008; Pluchino
et al., 2005). Rather, two independent groups have reported
that the effects of NSC transplant in this model are due to unex-
pected immunosuppressive properties of the NSCs (Einstein
et al., 2007; Pluchino et al., 2005). Both these studies and subse-
quent in vitro studies have implicated T cells as the target of this
immunosuppression, by inhibiting T cell proliferation and differ-
entiation or inducing T cell apoptosis (Einstein et al., 2007;
Neuron
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convincing piece of evidence from these studies is the observa-
tion that primed T cells from amouse treated with NSCs are defi-
cient in their ability to adoptively transfer disease, demonstrating
a lasting inhibition of the encephalitogenicity of the T cells rather
than an effect specific to their environment (Einstein et al., 2007).
These studies serve to remind us that immune-NSC signaling is
not a one-way street and that NSCs also exert some control over
local immune responses.
Stroke and the Abortive Induction of Native
Neurogenesis
Stroke increases the number of newborn neurons in peri-infarct
areas of the cortex and striatum, presumably through the induc-
tion of injury-related signals that recruit the migration of NPCs
from the ventricular zone into the damaged parenchyma (Arvids-
son et al., 2002; Jin et al., 2006; Parent et al., 2002; Zhang et al.,
2001). These newborn cells persist for at least 5 weeks after
stroke and ultimately expressmarkers ofmature neurons (Parent
et al., 2002). Furthermore, those cells that persist in the striatum
express specific markers of medium spiny neurons, the major
neuronal cell type in the striatum (Arvidsson et al., 2002; Parent
et al., 2002), and demonstrate appropriate neurotransmitters,
synaptic structures, and the ability to send and receive electric
signals (Hou et al., 2008). The source of these cells is the SVZ,
where stroke appears to increase the pool of NSCs by inducing
a switch from asymmetric to symmetric amplifying divisions
(Zhang et al., 2004). In spite of this native response, the number
of newborn cells surviving under normal conditions in the stria-
tum or cortex is very low (on the order of a few dozen to a few
hundred per mm3) (Arvidsson et al., 2002; Jin et al., 2006; Parent
et al., 2002). In contrast, the increase in newborn neurons within
the SVZ proper is more robust with a 50% increase over the
2 weeks after stroke, corresponding to an extra 1000 cells/mm3
(Zhang et al., 2001). These numbers suggest that a majority of
the new cells generated in the SVZ in response to stroke are
not recruited into the parenchyma and are ultimately eliminated.
Although not without controversy, studies using different
NSAIDs now indicate that anti-inflammatory treatments around
the time of stroke are able to enhance the accumulation of
newborn neurons (Hoehn et al., 2005; Kauppinen et al., 2009;
Kim et al., 2009; Liu et al., 2007). Currently, only one of these
groups has examined functional outcome, and found that mino-
cycline was protective (Liu et al., 2007). However, it is unclear
whether the behavioral protection was due to increased neuro-
genesis, decreased inflammation, or other factors. One further
study has examined NSC transplants and has shown, similar
to studies in MS models (Einstein et al., 2007; Pluchino et al.,
2005), that NSC transplants are protective in stroke though few
new neurons were produced and there is speculation, largely
on the basis of earlier reports that NSCs can be immunomodula-
tory (see MS section above), that the protection is due to anti-
inflammatory effects of the transplanted NSCs (Lee et al., 2008).
Neurodegenerative Disease and Chronic Microglial
Activation
Many neurodegenerative diseases, including Alzheimer’s and
Parkinson’s disease (AD and PD), are accompanied by increas-
ingly widespread neuroinflammation characterized by chronic
activation of microglia and production of proinflammatory cyto-kines (see accompanying article in this issue of Neuron from
Lucin andWyss-Coray, 2009). Studies in multiple animal models
(and putatively in PD patients) report a decrease in neurogenesis
during disease, especially in the SVZ and olfactory bulb (Baker
et al., 2004; Hoglinger et al., 2004; Winner et al., 2004). Whether
inflammation contributes to this phenotype is unclear, because
the loss of dopamine may itself lead to decreased neurogenesis
(Borta and Hoglinger, 2007). In AD, there is no current consensus
on whether neurogenesis is impacted. In amajority (but not all) of
animal models, neurogenesis is inhibited, most likely after the
beginning of amyloid plaque deposition, the primary patholog-
ical hallmark of AD, but human studies have largely failed to
confirm these results (Kuhn et al., 2007). These conflicts await
resolution, but may be related to age, length of disease, and
different characteristics of the different disease models, each
of which mimics loss of neurons but does not recapitulate the
native neurodegenerative process.
Curiously, in both PD and AD, there are behavioral manifesta-
tions in humans suggestive of defects in hippocampal networks
that are influenced by neurogenesis (decreased spatial memory
and high rates of depression) as well as deficits in olfactory
networks that are also influenced by adult neurogenesis (Gab-
ryelewicz et al., 2007; Hawkes, 2006; Matsuda, 2007; Poewe,
2008). In fact, loss of olfactory acuity has been cited as one of
the earliest clinical manifestations of degeneration in both AD
and PD (Hawkes, 2006). Similarly, symptoms of depression
and changes in hippocampal volume and activity are often
seen as antecedents of clinical diagnosis for both these diseases
(Bruck et al., 2004; Gabryelewicz et al., 2007; Matsuda, 2007;
Poewe, 2008). Though highly speculative, it is possible that
inflammation impairs neurogenesis in these areas and that
NPC dysregulation contributes to the early disease biomarkers
as well as to the overall degenerative process, particularly within
the respective neurogenic areas of the brain.
Transplantation of NSCs and Inflammation
The use of NSCs for transplantation has been suggested as
a therapy for many neurodegenerative diseases (Ormerod
et al., 2008). In general, the goal of such a transplant would be
to replace cells lost during the disease process, usually neurons
or oligodendrocytes. One encouraging sign of this approach in
the CNS is that allogeneic cellular grafts into the CNS can exhibit
long-term survival even after immunosuppressive withdrawal
(Chen and Palmer, 2008). In addition to cell replacement, stem
cell therapy may be used to improve outcome by other means.
NSCs can be genetically modified to produce supportive growth
factors and cytokines to protect the remaining cells from loss
rather than to replace them (as reviewed in Ormerod et al.,
2008). Furthermore, the unexpected anti-inflammatory proper-
ties of NSC transplants may serve to improve disease state by
modifying the injury or inflammatory process without having to
differentiate at all (Einstein et al., 2007; Lee et al., 2008; Pluchino
et al., 2005).
The environment of the diseased brain almost invariably has
an inflammatory component that could affect the outcome of
the transplant in several ways. It is possible that inflammation
may benefit the efficacy of a transplant by directing NSCs to
the site of injury. NSCs express a variety of chemokine receptorsNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 85
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during CNS inflammation (Bailey et al., 2006), suggesting that
NSCs could be specifically recruited to areas of injury or inflam-
mation. Indeed, NSCs are able to migrate in response to chemo-
kines generated after injury in vivo, with particularly important
roles for the chemokines CCL2 and CXCL12 (Imitola et al.,
2004; Yan et al., 2007). Recently, it has been shown in multiple
disease models that even NSCs injected intravenously are able
to infiltrate sites of CNS injury (Chu et al., 2004; Fujiwara et al.,
2004; Lee et al., 2005; Pluchino et al., 2003). Although vascular
delivery is not the most efficient method of delivering cells
(Tang et al., 2003), the obvious advantages of intravenous
administration (should it prove compellingly effective for
unknown reasons) are its clinical ease and lack of invasiveness.
Inflammation in the CNS is likely to limit the efficacy of current
transplant strategies. The preponderance of evidence indicates
that transplanted NSCs will be ineffective at generating neurons
in particular, given the inhibitory effect of proinflammatory
signaling on neurogenesis in adult animals (Ekdahl et al., 2003;
Monje et al., 2002). Furthermore, it should also be recognized
that not only will transplanted cells encounter an inflamed envi-
ronment, but they may contribute to it. The use of allogeneic
embryonic stem cells or fetal-brain-derived NSCs is widely
contemplated and entering clinical trials, yet these cells would
not be immunologically matched to the host. There is even
a long history of both experimental and clinical use of xenografts
(cells from another species) with mixed outcome. There should
be careful consideration of the source of cells for transplantation
into the CNS, and in particular the immune response that an allo-
graft or xenograft may elicit from the host after transplant.
MHC I is a critical mediator of graft rejection and plays a key
role in the ability of cytotoxic T cells and natural killer (NK) cells
to recognize ‘‘nonself’’ tissue, including the presence of foreign
MHC as well as the absence of ‘‘self’’ MHC. The constitutive
expression of MHC I on NSCs has been reported (Corriveau
et al., 1998; Johansson et al., 2008). Although others have found
expression weak or undetectable under baseline conditions
(Hori et al., 2003; Mammolenti et al., 2004; Preynat-Seauve
et al., 2009), there is wide consensus that exposure to inflamma-
tory cytokines such as IFN-g and TNF-a stimulatesMHC expres-
sion in NSC (Hori et al., 2003; Johansson et al., 2008; Mammo-
lenti et al., 2004; Preynat-Seauve et al., 2009). This renders the
NSC recognizable by T cells or NK cells in vitro, leading to
classical immune-mediated cytolysis. (Mammolenti et al.,
2004; Preynat-Seauve et al., 2009). Although some have argued
that stem cell grafts would be ‘‘invisible’’ due to the lack of MHC
expression, the inflammatory contexts in which these cells would
be used virtually guarantee that transplanted NSCs would
express high levels of MHC and would be readily recognized
by infiltrating T cells.
Despite differences in adaptive immune signaling between the
periphery and the CNS, the CNS is still fully capable of rejecting
xenografts and allografts (reviewed in Chen and Palmer, 2008).
For example, in one study, xenograft transplants of embryonic
brain tissue into the brains of mice were rejected, but allografts
survived at least 42 days (Mirza et al., 2004). Allograft survival
is due in part to the low immune surveillance and active inhibition
of T cell responses in the CNS (Bailey et al., 2006), but it may also86 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.be due to the properties of the transplanted cells themselves.
One study has reported that NSCs transplanted into the kidney
capsule survive at least 28 days, whereas control CNS tissue
is rejected in the same time frame (Hori et al., 2003). Determining
the properties of cells that allow for relatively long survival times
in some allografts, and how these conditions might be leveraged
to improve outcome, is crucial to moving forward with
CNS transplantation using mass-produced allogeneic cellular
reagents.
Ultimately, however, allografts do elicit an immune response in
the CNS and this can lead to graft rejection. In a rat model of
spinal cord injury, NSC allografts were ultimately rejected after
an extended period of growth and maturation (Theele et al.,
1996). Even when grafts survive, numerous CD45+ cells are
observed around the allograft in both mice (Ideguchi et al.,
2008) and humans who received grafts of fetal nigral tissue to
treat PD (Kordower et al., 1997). Numerous immune lineage cells
were observed around the graft, including macrophages, T cells,
and B cells, and although the grafts survived over a period of
18 months in humans, even after withdrawal of immunosuppres-
sion, the consequences of this chronic inflammatory state
are unlikely to be beneficial. Indeed, when compared to
syngeneic grafts, allografts not only show decreased survival
(Muraoka et al., 2006; Theele et al., 1996), but also decreased
migration away from the transplant site and decreased differen-
tiation of neurons (Muraoka et al., 2006), an effect that can be
partially prevented using the immune-suppressive effects of
cyclosporine A (Ideguchi et al., 2008; Theele et al., 1996). These
results suggest that immune suppression and accompanying
risks of chronically compromised immune function may be a
necessary reality for allografts to survive and efficiently generate
neurons. However, we await studies to determine whethermilder
immunosuppressants or the tapering off of immunosuppression
is compatible with long-term efficacy.
The use of patient-derived fibroblasts to generate induced
pluripotent stem cells (iPSCs) (Takahashi et al., 2007) may ulti-
mately supersede allograft transplantation. There is a great
deal of excitement over the use of iPSCs for transplant therapy
in a variety of diseases. iPSC lines have been created from
patients with neurological diseases such as PD, amyotrophic
lateral sclerosis (ALS), and spinal muscular atrophy (SMA)
(Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009).
One obvious advantage of using these cells for transplant would
be that they are a perfect immunological match to the host.
However, they could have disadvantages as well; neurons
derived from iPSCs from SMA patients have defects in cell
survival in vitro (Ebert et al., 2009), likely as a result of the genetic
mutation that causes this disease. In diseases arising from
a single or well-defined genetic alteration, the mutated genes
could be altered in the iPSCs prior to transplant. This has been
shown to be an effective strategy in mice with sickle cell anemia
treated with iPSCs that were genetically altered to express
normal hemoglobin (Hanna et al., 2007). However, it is worth
noting that the normal protein produced in a deficient host could
be seen by the immune system as nonself and be targeted for an
immune response. Whether this type of immune attack of an
altered autologous cell will occur in this NSC-transplant scenario
is entirely unknown, but will be important to determine prior to
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cases of neurodegenerative diseases are idiopathic with no
known genetic anomaly. It is unclear whether patient-derived
cells in these diseases will carry an intrinsic defect, and whether
this would need to be corrected to allow normal function and
survival. In this case, allografts of normal cells, even if not
perfectly immunologically matched, may be preferable. A great
deal of research still needs to be done to determine the best
type of cells to transplant for any given disease, and possibly
for any given patient. The most fundamental of these experi-
ments are those that critically test whether stem-cell-based
treatments are in fact beneficial.
To date, there has been limited exploration of iPSCs in treat-
ments for neurologic disease. In a toxin-induced model of PD
in rats (Wernig et al., 2008), the cells survived and integrated in
the host brain, but the authors noted the appearance of tera-
tomas arising from undifferentiated cells (Wernig et al., 2008).
Addressing the propensity of iPSCs (or indeed any undifferenti-
ated cell regardless of source) to form cancers following
transplantation will be key to moving stem-cell-based therapies
into the clinic.
Proinflammatory Cytokines and Their Impact
on NSCs and Neurogenesis
One of the common effects of immune activation is the produc-
tion of cytokines. In the CNS, cytokines are primarily produced
by activated microglia, but are also generated by astrocytes
and infiltrating immune cells (Bailey et al., 2006). Cytokines are
the secreted molecules that mediate communication between
immune cells and between immune system and host. Cytokines
encompass a broad class of signaling molecules that have the
potential to influence an immense variety of signals that regulate
NSC function, including growth factor production, electrical
activity, synaptic function, and axonal path finding. Cytokine-
mediated effects on neural development are discussed in detail
elsewhere in this issue, and we refer interested readers to the
review by Deverman and Patterson (2009) for further information.
For the purposes of this review, we will limit our discussion to an
overview of the cardinal proinflammatory cytokines that are
known to have a prominent inhibitory effect on adult neurogene-
sis in vivo and that have been strongly implicated in the injury and
disease models discussed above. These include TNF-a, IL-6,
and IL-1b.
TNF-a
TNF-a is well known for its proinflammatory functions in the
immune system, where it is produced by a variety of cells
including T cells and macrophages. In the brain, TNF-a has the
paradoxical ability to both protect and destroy neurons (McCoy
and Tansey, 2008). TNF-a signals through two distinct receptors:
TNF-a receptor 1 (TNFR1), the major mediator of proinflamma-
tory and proapoptotic functions of TNF-a, and TNFR2, which
activates more progrowth and survival pathways.
Reported effects of TNF-a on NSC proliferation and differenti-
ation are highly conflicting, with various groups reporting
increases or decreases in proliferation and the differentiation of
neurons (Ben-Hur et al., 2003; Bernardino et al., 2008; Liu
et al., 2005; Widera et al., 2006). The source of this variation is
not entirely clear but could be related to the species of cell,age or location of isolation, amount of time in vitro, concentration
or time of treatment during differentiation, or the cell’s predom-
inant expression of TNFR1 versus TNFR2. The only consistency
seems to be that several groups have now reported that TNF-a
can induce apoptosis in NSCs or newborn neurons via TNFR1
(Cacci et al., 2005; Sheng et al., 2005; Widera et al., 2006).
TNFR1 signaling, but not that of TNFR2, has been demonstrated
to inhibit neurogenesis in the normal hippocampus (Iosif et al.,
2006). In contrast, direct injection of TNF-a into the ventricles
increased proliferation of SVZ cells (Wu et al., 2000), though it
is not immediately clear which cell lineage was proliferating
(immune versus neural progenitor), and whether this effect was
TNFR1 or TNFR2 mediated was not addressed.
There is significant evidence that TNF-a signaling plays a role
in a variety of disease processes, and whether that effect is posi-
tive or negative appears to depend on whether activation of
TNFR1 or TNFR2 predominates. For example, TNFR1-deficient
mice have increased neurogenesis in the hippocampus following
seizure, but TNFR2-deficient mice have decreased seizure-
induced neurogenesis (Iosif et al., 2006). Similarly, TNFR1-defi-
cient mice have increased proliferation of newborn neurons in
the SVZ following stroke (Iosif et al., 2008). However, the infusion
of anti-TNF-a antibody after stroke to block all TNF-a signaling is
detrimental to the survival of stroke-induced newborn neurons
(Heldmann et al., 2005), likely due to the loss of TNFR2 signaling.
TNF-a has a similar role in the generation of new oligodendro-
cytes, because TNFR2 signaling is specifically required for re-
myelination by OPCs in a toxin-induced model of demyelination
(Arnett et al., 2001).
IL-6
IL-6 is a member of a family of cytokines that signal through the
gp130 receptor that includes ciliary neurotrophic factor (CNTF)
and leukemia inhibitory factor (LIF). CNTF and LIF have roles in
promoting NSC self-renewal and astrocyte differentiation from
NSCs (Shimazaki et al., 2001; Taga and Fukuda, 2005). Because
they all use the same signal transducing molecule (gp130) to
signal into the cell, it is likely that IL-6 also promotes the gener-
ation of astrocytes. In vivo, gp130-deficient animals die perina-
tally and demonstrate a lack of astrocytes in the CNS, supporting
a role for this family of cytokines in astrocyte differentiation
(Ware et al., 1995). However, IL-6-deficient mice do not have
constitutive deficits in the numbers of astrocytes, although
they appear to have reduced activation in response to injury
(Klein et al., 1997).
IL-6 also has a direct effect on adult or neonatally derived
NSCs in vitro, increasing astrocyte production and decreasing
neuron production (Monje et al., 2003; Nakanishi et al., 2007).
Blocking IL-6 in media conditioned by normal microglia inhibits
the astrocyte-inducing properties of the conditioned media (Na-
kanishi et al., 2007). Furthermore, the reduction of neurogenesis
caused by LPS-activated microglial-conditioned media is atten-
uated by blocking IL-6 (Monje et al., 2003).
In vivo, there is little direct evidence linking IL-6 production
with alterations in neurogenesis or gliogenesis observed during
disease. However, mice with chronic overproduction of IL-6 by
astrocytes demonstrate a reduction in hippocampal neurogene-
sis (Vallieres et al., 2002). Although profound astrogliosis was
observed in the hippocampus, it did not appear that NSCsNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 87
Neuron
Reviewwere differentiating into astrocytes more frequently in IL-6-over-
producing hippocampi (Vallieres et al., 2002). This could provide
support for a recent hypothesis that suggested that gp130
signaling does not promote commitment of NSCs to a glial
fate, but rather promotes astrocyte differentiation from an
already committed glial progenitor (Shimazaki et al., 2001). The
role of IL-6 in disease-induced changes in neurogenesis
warrants further study.
IL-1b
The IL-1 family of cytokines is known primarily for its role in proin-
flammatory responses, but recent emerging evidence suggests
it has interesting roles in normal learning and memory as well
as changes induced by inflammation and stress (McAfoose
andBaune, 2009). The strongest evidence for an anti-neurogenic
effect of IL-1 comes from studies of animal models of depres-
sion. Chronic mild stress of animals induces depression-like
behaviors and decreases in neurogenesis in the hippocampus,
both of which are dependent on IL-1b (Goshen et al., 2008;
Koo and Duman, 2008). Treatment of mice with IL-1b either intra-
cerebroventricularly (i.c.v.) or subcutaneously is sufficient to
decrease hippocampal neurogenesis (Goshen et al., 2008; Koo
and Duman, 2008). However, mice overexpressing soluble IL-1
receptor antagonist (IL-1ra), which blocks normal IL-1 signaling
in the brain, also show decreased neurogenesis in the hippo-
campus, both constitutively and following seizure, and deficits
in hippocampal-dependent learning and memory (Goshen
et al., 2007; Spulber et al., 2008). These results suggest that
constitutive IL-1 signaling is important for normal hippocampal
neurogenesis and function. It appears that responses to IL-1b
are highly dose dependent, because low doses of IL-1b infused
i.c.v. increase performance on hippocampal-dependent tasks
while high doses inhibit performance (Goshen et al., 2007).
Summary
The complexities of immune states that accompany neurological
disease or injury make it difficult to draw concise conclusions
about immune signaling and the effects on NSC. In the end,
the specific therapeutic or regenerative goal will define whether
native immune signaling in a given context is ‘‘bad’’ or ‘‘good.’’
One consistent finding is that the acute innate proinflammatory
signaling cascade strongly inhibits the production and retention
of new neurons in the adult brain. At the same time, this signaling
appears to favor the recruitment and differentiation of OPCs,
a valuable natural component of the injury response.Many verte-
brate species are able to fully regenerate lost brain tissue, and
the reasonwhy neurogenesis is so strongly inhibited inmammals
remains obscure, but immune signaling seems a likely contrib-
utor to the phenomenon. Evolutionary pressures may have
selected for injury response mechanisms that favor remyelina-
tion and rescue of preexisting neural networks over the formation
of entirely new networks. The refinement that occurs over years
of learning and adaptation within higher-order adult neural
networks would be absent in newly generated networks. In one
sense, the consequences of complete neural regeneration may
actually be loss of function—at least until the new networks are
‘‘retrained’’ by subsequent experience and become usefully inte-
grated within the preexisting networks. In childhood, functional
refinement takes years, perhaps even 2 decades, before many88 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.neural networks achieve their peak capabilities. One is left
wondering if aggressive regenerative approaches are realistic
goals for all diseases if such time frames are needed to realize
an improvement. Obviously, this is highly speculative since
even experimental models have yet to achieve this level of re-
generation, but it is also a notion worth holding in reserve as
we begin to interpret the short-term outcomes following the
aggressive redirection of NSCs into a neuronal fate in experi-
mental models.
Despite the uncertainties, the failure of the brain to natively
regenerate and the possibility that we might leverage stem cell
biology to overcome this failure remains a central driving force
in NSC research. Here, the injury environment and related
immune signaling are facts of life that must be addressed, and
future studies can no longer rely on the naive supposition that
the brain will efficiently utilize injected stem cells as substrates
for neural network regeneration. It is increasingly obvious that
the CNS is not able to efficiently generate replacement neurons
without aggressive interventions that overcome the natural
inhibition of neurogenesis within the injured or diseased CNS.
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